Swedish Scientists Achieve Breakthrough in Stem Cell Therapy for Type 1 Diabetes

Swedish researchers have reported a significant advancement in the treatment of type 1 diabetes, demonstrating that stem cell-derived insulin-producing cells can restore natural blood sugar regulation in patients with the condition. The findings, published in a peer-reviewed journal, represent a potential step toward therapies that could reduce or eliminate the need for daily insulin injections in some individuals.

The study, conducted by scientists at Karolinska Institutet and Uppsala University in collaboration with biotechnology firm Biocrine, involved transplanting laboratory-grown pancreatic islet cells derived from human stem cells into patients with type 1 diabetes. These cells, designed to mimic the function of healthy insulin-producing beta cells, were delivered via a minimally invasive procedure into the forearm muscle, where they integrated with the body’s blood supply.

According to the research team, the transplanted cells began producing insulin in response to blood glucose levels within weeks of implantation. In the first six patients treated, insulin production was detectable and responsive to meals, with some individuals showing reduced reliance on external insulin administration. No severe adverse events related to the transplant procedure were reported during the observation period.

We are seeing the first evidence that stem cell-derived islets can survive, function, and be regulated by the body’s own glucose levels in patients with type 1 diabetes.

Dr. Anna Edelvik, lead researcher, Karolinska Institutet

Type 1 diabetes is an autoimmune condition in which the body’s immune system destroys insulin-producing beta cells in the pancreas, requiring lifelong management through insulin therapy, blood sugar monitoring, and dietary control. While current treatments are effective at managing the disease, they do not restore natural insulin production and carry risks of hypoglycemia and long-term complications.

This approach aims not just to manage blood sugar, but to restore the body’s innate ability to regulate it — a fundamental shift in how we treat type 1 diabetes.

Professor Per-Ola Carlsson, Uppsala University

The cells used in the trial were manufactured under strict laboratory conditions to ensure purity and functionality. Researchers emphasized that the cells were not genetically modified beyond what is necessary to direct their development into pancreatic progenitors, and that all batches underwent rigorous testing for sterility, potency, and safety prior to transplantation.

Immune suppression remains a key challenge in cell-based therapies for type 1 diabetes, as the autoimmune response that destroyed the original beta cells could potentially attack the new transplants. To address this, patients in the study received short-term immunosuppressive therapy following the procedure, a standard precaution in islet transplantation trials. Researchers noted that future iterations of the therapy may incorporate immune-protective strategies, such as encapsulation devices or localized immune modulation, to reduce reliance on systemic drugs.

The trial is ongoing, with plans to expand to additional patients and evaluate long-term graft survival, insulin independence rates, and safety over multiple years. Researchers cautioned that while the results are encouraging, the therapy remains investigational and is not yet available outside of clinical study settings.

We are optimistic but cautious. What we have is a proof of concept that biological insulin replacement is feasible, but much work remains to optimize durability, scalability, and accessibility.

Dr. Anna Edelvik

The study was funded by the Swedish Research Council, the European Union’s Horizon Europe program, and private foundations focused on diabetes research. Findings were published in the journal Nature Medicine in April 2026, following peer review. Independent experts in endocrinology and regenerative medicine have noted the work as a meaningful contribution to the field, while emphasizing the need for further validation in larger, diverse cohorts.